We are live on ! Find out more
SPRO icon

Spero Therapeutics
SPRO

48 hedge funds and large institutions have $20.6M invested in Spero Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 7

0.05% more ownership

Funds ownership: 27.47% → 27.52% (+0.05%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

16% less capital invested

Capital invested by funds: $24.6M → $20.6M (-$3.98M)

20% less funds holding

Funds holding: 60 → 48 (-12)

77% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 13

79% less call options, than puts

Call options by funds: $30K | Put options by funds: $145K

Holders
48
Holders Change
-12
Holders Change %
-20%
% of All Funds
0.76%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
15
Reduced
7
Closed
13
Calls
$30K
Puts
$145K
Net Calls
-$115K
Net Calls Change
-$271K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$623K
2
AFM
Anson Funds Management
Texas
+$544K
3
BCM
Bridgeway Capital Management
Texas
+$184K
4
Group One Trading
Group One Trading
Illinois
+$136K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$135K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$639K
2
OMC
Oasis Management Company
Cayman Islands
-$498K
3
XT
XTX Topco
Cayman Islands
-$380K
4
VF
Virtu Financial
New York
-$59K
5
TRCT
Tower Research Capital (TRC)
New York
-$54.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Bourgeon Capital Management
Connecticut
$37.1K +$20.9K +12,500 +95%
Invesco
27
Invesco
Georgia
$27.5K +$11.6K +6,906 +57%
Bank of America
28
Bank of America
North Carolina
$26.7K +$17.5K +10,479 +132%
Morgan Stanley
29
Morgan Stanley
New York
$22.1K -$3.09K -1,847 -11%
Dimensional Fund Advisors
30
Dimensional Fund Advisors
Texas
$17K – – –
TYCC
31
Texas Yale Capital Corp
Florida
$14.5K – – –
Russell Investments Group
32
Russell Investments Group
United Kingdom
$9.28K – – –
Federated Hermes
33
Federated Hermes
Pennsylvania
$7.04K +$7.94K +4,744 +4,352%
Osaic Holdings
34
Osaic Holdings
Arizona
$4.86K +$79 +47 +2%
WWP
35
WR Wealth Planners
Missouri
$3.77K +$4.35K +2,600 New
CFB
36
Cullen/Frost Bankers
Texas
$2.9K – – –
FDCDDQ
37
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.01K +$1.17K +700 New
TRCT
38
Tower Research Capital (TRC)
New York
$1K -$54.6K -32,623 -98%
AF
39
Allworth Financial
California
$870 – – –
Wells Fargo
40
Wells Fargo
California
$741 +$172 +103 +25%
TWC
41
TD Waterhouse Canada
Ontario, Canada
$456 – – –
PP
42
PFS Partners
New Jersey
$358 – – –
BHWM
43
Beaird Harris Wealth Management
Texas
$293 – – –
HWA
44
Heritage Wealth Advisors
Virginia
$271 – – –
US Bancorp
45
US Bancorp
Minnesota
$219 – – –
NA
46
NewEdge Advisors
Louisiana
$145 – – –
IRC
47
Investors Research Corp
Georgia
$73 – – –
OMC
48
Oasis Management Company
Cayman Islands
– -$498K -288,000 Closed
VF
49
Virtu Financial
New York
– -$59K -34,369 Closed
TSS
50
Two Sigma Securities
New York
– -$40.7K -23,523 Closed
1
2
3

SPRO Hedge Fund Activity: Q1 2023 in Review

48 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2023, worth a combined $20.6M — down 16% from $24.6M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of SPRO and 3 opened new positions — a net loss of 10 holders — while 7 trimmed existing stakes and 15 added.

The largest buyer was Vanguard Group, adding an estimated $623K. The largest seller was Millennium Management, cutting an estimated $639K.

  • 48 institutional investors held Spero Therapeutics (SPRO) as of Q1 2023, down from 60 in Q4 2022.
  • Funds reported $20.6M of Spero Therapeutics stock for Q1 2023, down 16% quarter-over-quarter.
  • 3 funds opened new Spero Therapeutics positions in Q1 2023 and 13 closed out, a net change of -10 holders.
  • The largest Spero Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $623K added.
  • The largest Spero Therapeutics seller in Q1 2023 was Millennium Management, an estimated $639K sold.

Based on aggregated 13F filings for Q1 2023.